Literature DB >> 9104974

Minimal operative mortality in patients undergoing coronary artery bypass with significant left ventricular dysfunction by maximization of metabolic and mechanical support.

G E Cimochowski1, M D Harostock, P J Foldes.   

Abstract

Between January 1, 1992, and January 23, 1996, 111 consecutive patients with severe left ventricular dysfunction underwent isolated coronary artery bypass grafting. The ejection fraction in these patients ranged from 10% to 34% (mean 27.9% +/- 5.4%); in 18 patients the value was less than 20%. The high operative mortality rate (7.6% in Society of Thoracic Surgeons database) in this group of patients at high risk was targeted for reduction by provision of, in addition to the usual inotropic support, progressively more intensive metabolic and mechanical support. The metabolic support consisted of triiodothyronine; glucose, insulin, and potassium; aspartate/glutamate in the cardioplegic solution; and warm-cold-warm/antegrade-retrograde-antegrade cardioplegia. Mechanical support included liberal use of the intraaortic balloon pump, use of a new occlusive retrograde cardioplegia catheter, ultrafiltration to remove myocardial depressant factors, and, finally, delayed sternal closure. The operative mortality rate was 1.8% (2/111). Complications included reoperation because of bleeding (3.6%, 4/111), mediastinitis (1.8%, 2/111), and stroke (0.9%, 1/111) and there were no occurrences of new postoperative acute renal failure (0.0%, 0/111). The intensive care unit stay was 2.2 +/- 0.9 days with a length of stay in the hospital of 13.7 +/- 22.1 days. These techniques done before operation, intraoperatively, and postoperatively optimize the milieu of the depressed left ventricle by maximizing perioperative high-energy phosphate bonds; increasing the effectiveness of inotropic agents; unloading the left ventricle by chemical, metabolic, and mechanical support; and removing known myocardial depressant factors, which reduced the operative mortality rate to 1.8% compared with 7.6% as reported in the Society of Thoracic Surgeons' database.

Entities:  

Mesh:

Year:  1997        PMID: 9104974     DOI: 10.1016/S0022-5223(97)70222-8

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Protecting the damaged heart during coronary surgery.

Authors:  D J Wheatley
Journal:  Heart       Date:  2003-04       Impact factor: 5.994

2.  Stabilizing endothelium of donor hearts with fusogenic liposomes reduces myocardial injury and dysfunction.

Authors:  Tathyana F Fensterer; W Brent Keeling; Phani K Patibandla; Sathnur Pushpakumar; Gustavo Perez-Abadia; Philip Bauer; Chirag V Soni; Gary L Anderson; Claudio Maldonado
Journal:  J Surg Res       Date:  2012-10-30       Impact factor: 2.192

Review 3.  Myocardial revascularization as a therapeutic strategy in the patient with advanced ventricular dysfunction.

Authors:  F A Mitropoulos; J A Elefteriades
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

4.  Cardiac resynchronization therapy as an adjunct to conventional surgical treatment for heart failure.

Authors:  Ugo F Tesler; Guido Lanzillo; Eugenio Novelli; Gheorge Cerin; Marco Diena
Journal:  Tex Heart Inst J       Date:  2008

5.  Effects of myocardial viability and left ventricular remodeling on survival of patients with heart failure and reduced ejection fraction after coronary artery bypass grafting.

Authors:  Jian Cao; Ran Dong; Kui Zhang; Hongjia Zhang
Journal:  Cardiovasc Diagn Ther       Date:  2020-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.